Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
ASLN Stock: Why It Fell Over 25% Today
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development